The year ended with the capital markets faltering and an erosion of our share price. To preserve our capital, we took immediate action in early 2019 and implemented a reduction in expenditures. Cost reduction steps included:•Suspension of Directors fees•Suspension of instrument development costs•Re-organization and reduction in staff and consultants•Other general reduction in expenses and travel restrictions
Ann: FDA Breakthrough Device Designation, page-193
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
